Triplet Succeeds in BRAF-Mutant Melanoma

]]>(MedPage Today) -- Adding the PD-L1-directed immunotherapy atezolizumab (Tecentriq) to a targeted combination improved progression-free survival (PFS) for advanced melanoma patients with a BRAF V600 mutation, a phase III trial showed.In over...